 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| mRNA-4157 / Merck (MSD), Moderna
Enrollment open, Enrollment change: KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov) - Jan 8, 2024
P1, N=242, Recruiting, Sponsor: ModernaTX, Inc.
Active, not recruiting --> Recruiting | N=108 --> 242
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, Metastases: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov) - Dec 18, 2023
P1, N=138, Completed, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Recruiting | N=108 --> 242 Active, not recruiting --> Completed
- Effectiveness and Cost-Effectiveness Analysis of 11 Treatment Paths, Seven First-Line and Three Second-Line Treatments for Chinese Patients with Advanced Wild-Type Squamous Non-Small Cell Lung Cancer: A Sequential Model () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1360;
A microsimulation-based sequential model was developed to estimate costs and quality-adjusted life years (QALY) for treatment sequences with first-line platinum- and paclitaxel-based chemotherapy (SC) with or without nedaplatin, tislelizumab, camrelizumab, sintilimab, sugalimumab or pembrolizumab, followed by second-line docetaxel, tislelizumab or nivolumab. PED and CAD are the most effective and cost-effective treatment sequence, respectively; pembrolizumab+SC and camrelizumab+SC are the most effective and cost-effective first-line choice, respectively; tislelizumab is the most effective and cost-effective second-line choice.
- || mRNA-4157 / Merck (MSD), Moderna
Enrollment closed, Combination therapy: KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov) - Feb 24, 2023
P1, N=108, Active, not recruiting, Sponsor: ModernaTX, Inc.
PED and CAD are the most effective and cost-effective treatment sequence, respectively; pembrolizumab+SC and camrelizumab+SC are the most effective and cost-effective first-line choice, respectively; tislelizumab is the most effective and cost-effective second-line choice. Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov) - Jan 20, 2023
P1, N=136, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023
- ||||| pembrolizumab subcutaneous (MK-3475 SC) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Metastases: KEYNOTE-A86: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) (clinicaltrials.gov) - Nov 8, 2022
P3, N=512, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023 Recruiting --> Active, not recruiting
- || mRNA-4157 / Merck (MSD), Moderna
Trial completion date, Trial primary completion date, Combination therapy: KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov) - Aug 24, 2022
P1, N=143, Recruiting, Sponsor: ModernaTX, Inc.
Recruiting --> Active, not recruiting Trial completion date: Jun 2022 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2025
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov) - Feb 25, 2022
P1, N=136, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2022 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2025 Trial completion date: Apr 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Feb 2023
- |||||||||| pembrolizumab subcutaneous (MK-3475 SC) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Metastases: Phase 3 study of pembrolizumab SC versus pembrolizumab IV, administered with platinum doublet chemotherapy, in 1L metastatic squamous or nonsquamous NSCLC (EUDRACT) - Sep 2, 2021
P3, N=450, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- |||||| pembrolizumab subcutaneous (MK-3475 SC) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: KEYNOTE-A86: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) (clinicaltrials.gov) - Aug 1, 2021
P3, N=450, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Apr 2022 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Feb 2023 Not yet recruiting --> Recruiting
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov) - Jul 14, 2021
P1, N=136, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Trial completion date: Aug 2021 --> Apr 2022 | Trial primary completion date: Aug 2021 --> Apr 2022
- |||||||||| pembrolizumab subcutaneous (MK-3475 SC) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Metastases: KEYNOTE-A86: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) (clinicaltrials.gov) - Jul 8, 2021
P3, N=450, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || mRNA-4157 / Merck (MSD), Moderna
Enrollment change, Trial primary completion date, Combination therapy: KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov) - Feb 17, 2021
P1, N=142, Recruiting, Sponsor: ModernaTX, Inc.
Trial completion date: Aug 2021 --> Apr 2022 | Trial primary completion date: Aug 2021 --> Apr 2022 N=90 --> 142 | Trial primary completion date: Dec 2020 --> Jun 2022
- || mRNA-4157 / Merck (MSD), Moderna
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov) - Mar 24, 2020
P1, N=90, Recruiting, Sponsor: ModernaTX, Inc.
N=90 --> 142 | Trial primary completion date: Dec 2020 --> Jun 2022 Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Sep 2019 --> Dec 2020
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov) - Feb 27, 2020
P1, N=136, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Sep 2019 --> Dec 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Dec 2020 --> Aug 2021
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Enrollment change, Trial primary completion date, Metastases: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov) - Oct 18, 2018
P1, N=136, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Dec 2020 --> Aug 2021 Not yet recruiting --> Recruiting | N=36 --> 136 | Trial primary completion date: May 2019 --> Apr 2021
- | mRNA-4157 / Merck (MSD), Moderna
Trial completion date, Combination therapy, PD(L)-1 Biomarker: KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov) - Sep 19, 2018
P1, N=90, Recruiting, Sponsor: Moderna Therapeutics
Not yet recruiting --> Recruiting | N=36 --> 136 | Trial primary completion date: May 2019 --> Apr 2021 Trial completion date: Mar 2020 --> Jun 2021
- | Keytruda (pembrolizumab) / Merck (MSD)
New P1 trial, Metastases: Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (clinicaltrials.gov) - Sep 11, 2018
P1, N=36, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||| mRNA-4157 / Merck (MSD), Moderna
New P1 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov) - Oct 18, 2017
P1, N=90, Recruiting, Sponsor: Moderna Therapeutics